KPTI Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class drugs directed against nuclear transport and related targets to treat cancer and other diseases.

$8.76  -0.08 (-0.91%)
As of 05/13/2021 10:47:12 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  11/06/2013
Outstanding shares:  75,092,567
Average volume:  2,068,496
Market cap:   $615,008,124
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    48576U106
ISIN:        US48576U1060
Sedol:      BG3FZW0
Valuation   (See tab for details)
PE ratio:   -3.29
PB ratio:   12.84
PS ratio:   5.43
Return on equity:   361.75%
Net income %:   -126.67%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy